'Sinovac Data Encouraging, But More Details Needed'
"); jQuery("#212 h3").html("

"); jQuery(document).ready(function() { jwplayer.key='EKOtdBrvhiKxeOU807UIF56TaHWapYjKnFiG7ipl3gw='; var playerInstance = jwplayer("jquery_jwplayer_1"); playerInstance.setup({ file: "https://newsstatic.rthk.hk/audios/mfile_1569321_1_20210108174645.mp3", skin: { url: location.href.split('/', 4).join('/') + '/jwplayer/skin/rthk/five.css', name: 'five' }, hlshtml: true, width: "100%", height: 30, wmode: 'transparent', primary: navigator.userAgent.indexOf("Trident")>-1 ? "flash" : "html5", events: { onPlay: function(event) { dcsMultiTrack('DCS.dcsuri', 'https://news.rthk.hk/rthk/en/component/k2/1569321-20210108.mp3', 'WT.ti', ' Audio at newsfeed', 'WT.cg_n', '#rthknews', 'WT.cg_s', 'Multimedia','WT.es','https://news.rthk.hk/rthk/en/component/k2/1569321-20210108.htm', 'DCS.dcsqry', '' ); } } }); }); });
2021-01-08 HKT 12:36
Professor David Hui speaks to RTHK's Frances Sit
An adviser on the government's anti-pandemic efforts said on Friday that he is encouraged by the latest trial results for the Covid-19 vaccine made by China's Sinovac, but SAR officials need more information before clearing it for use in Hong Kong.
The Sinovac vaccine, which is expected to be the first one to arrive in the SAR, was found to be 78% effective during final-stage trials in Brazil involving some 12,000 health workers.
Speaking on an RTHK programme, infectious disease expert David Hui noted that the efficacy rate shown is better than the 50 percent threshold set for vaccines by the World Health Organisation.
He said the data mainly came from middle-aged people, with no information for the elderly or those with chronic diseases.
But he said this does not mean that the vaccine is ineffective, and he believes Hong Kong is on track for inoculations to start next month.
"This is certainly encouraging data, but they need to provide more information to the Department of Health, including the safety profile, all the side-effects, the ingredients of the vaccine etc., before approval," he said.
Hui said more useful information would have been available if the study had covered people across a wider range of ages, but other final-stage trials, including those for China's Sinopharm vaccine, also only involved people below 60.
He also said he understands that another batch of vaccines developed by Germany's BioNTech, which has carried out trials on people aged 18 to 85, will arrive in Hong Kong late next month.
On local Covid-19 infection trends, the Chinese University professor said the figures are dropping too slowly, and authorities need to speed up contact-tracing and quarantining.
He said it is helpful that around 100 officers from the disciplined services will be deployed to help with tracking down close contacts of patients from next week, and he hopes more can soon be trained up to assist with the task.
He said it is not too late to begin such efforts, saying the pandemic will not end so soon and faster contact-tracing can help Hong Kong prevent infections.
ZA Bank Brings Nasdaq Data To Hong Kong, Expanding US Stock Access And Investor Education
ZA Bank and Nasdaq have announced a collaboration aimed at enhancing digital wealth management in Hong Kong and interna... Read more
Hong Kong To Study One‑Stop Infrastructure For Equities, Bonds And Digital Assets
The Hong Kong Monetary Authority’s (HKMA) CMU OmniClear and the Hong Kong Exchange (HKEX) are set to begin a study on... Read more
Hong Kong To Issue First Stablecoin Licenses In March, Expand Crypto Regulation
Hong Kong will issue its first licenses for fiat-referenced stablecoin issuers in March and introduce new legislation l... Read more
MSIG Joins US$6B IFC Credit Insurance Facility To Boost Emerging Market Lending
MSIG USA and Mitsui Sumitomo Insurance (MSI Japan), together referred to as MSIG, have joined a new insurance-ba... Read more
Why The $2 Trillion Stablecoin Prediction Is Too Low
McKinsey estimates the stablecoin market will hit $2 trillion by 2028. But according to Sam Lin, COO of dtcpay, even th... Read more
RedotPay Eyes US IPO With Potential US$1 Billion Raise
RedotPay is reportedly exploring an IPO in the US that could raise more than US$1 billion, according to people famili... Read more
